Vifor Pharma

Vifor Pharma FCF Yield

Delisted·Dec 22, 2022

The Free Cash Flow Yield of Vifor Pharma (VIFN.SW) as of Nov 3, 2026 is 2.88 %. In the previous year, Free Cash Flow Yield was 0.37 % — a change of 687.50% (higher).

FCF Yield

2.88 %

YoY

687.50%

Last updated:

Free Cash Flow Yield of Vifor Pharma is 2021 2.88 % . Free Cash Flow Yield of Vifor Pharma was 2020 0.37 % . It decreases by 687.50% higher compared to the previous year.

The Vifor Pharma FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2014
2.67 CHF
Jan 1, 2015
3.33 CHF
Jan 1, 2016
-0.24 CHF
Jan 1, 2017
-0.26 CHF
Jan 1, 2018
-0.77 CHF
Jan 1, 2019
3.62 CHF
Jan 1, 2020
0.37 CHF
Jan 1, 2021
2.88 CHF
The Vifor Pharma FCF Yield history
YEARFCF YieldYoY
2.88 %+687.50%
0.37 %-89.91%
3.62 %-572.75%
-0.77 %+192.53%
-0.26 %+11.21%
-0.24 %-107.07%
3.33 %+24.96%
2.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

Free Cash Flow Yield of Vifor Pharma is 2.88 % in 2021.

Free Cash Flow Yield of Vifor Pharma changed from 0.37 % to 2.88 %, representing a 687.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Vifor Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vifor Pharma

All Key Metrics — Vifor Pharma